中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2015年
5期
375-378
,共4页
崔传亮%李思明%迟志宏%斯璐%盛锡楠%毛丽丽%连斌%王轩%唐碧霞%郭军
崔傳亮%李思明%遲誌宏%斯璐%盛錫楠%毛麗麗%連斌%王軒%唐碧霞%郭軍
최전량%리사명%지지굉%사로%성석남%모려려%련빈%왕헌%당벽하%곽군
肾肿瘤%肿瘤治疗方案%舒尼替尼%治疗结果
腎腫瘤%腫瘤治療方案%舒尼替尼%治療結果
신종류%종류치료방안%서니체니%치료결과
Kidney neoplasms%Antineoplastic protocols%Sunitinib%Treatment outcome
目的:观察舒尼替尼服药2周、停药1周方案(2/1方案)一线治疗转移性肾细胞癌患者的疗效及安全性。方法经病理证实的11例转移性肾透明细胞癌患者采用舒尼替尼2/1方案治疗,即舒尼替尼50 mg、1次/d,服药2周,停药1周,每6周为1个周期,持续使用至疾病进展或不良反应不能耐受。主要观察终点为无进展生存时间(PFS),次要终点为总生存时间(OS)、不良反应及客观缓解率。结果11例患者中,部分缓解5例,疾病稳定3例,疾病进展3例,客观缓解率为45.5%,疾病控制率为72.7%,中位PFS为17.0个月(95%CI为7.3~26.7个月),中位OS为26.0个月(95%CI为2.2~49.8个月)。主要不良反应为骨髓抑制(白细胞降低、血小板降低)、腹泻、黏膜炎和手足皮肤反应等,2例患者因不良反应舒尼替尼减量至37.5 mg、1次/d,无因不良反应停止治疗者。结论舒尼替尼2/1方案一线治疗转移性肾细胞癌患者的疗效较好,患者耐受性好,3~4度不良反应发生率较低,PFS有延长趋势。
目的:觀察舒尼替尼服藥2週、停藥1週方案(2/1方案)一線治療轉移性腎細胞癌患者的療效及安全性。方法經病理證實的11例轉移性腎透明細胞癌患者採用舒尼替尼2/1方案治療,即舒尼替尼50 mg、1次/d,服藥2週,停藥1週,每6週為1箇週期,持續使用至疾病進展或不良反應不能耐受。主要觀察終點為無進展生存時間(PFS),次要終點為總生存時間(OS)、不良反應及客觀緩解率。結果11例患者中,部分緩解5例,疾病穩定3例,疾病進展3例,客觀緩解率為45.5%,疾病控製率為72.7%,中位PFS為17.0箇月(95%CI為7.3~26.7箇月),中位OS為26.0箇月(95%CI為2.2~49.8箇月)。主要不良反應為骨髓抑製(白細胞降低、血小闆降低)、腹瀉、黏膜炎和手足皮膚反應等,2例患者因不良反應舒尼替尼減量至37.5 mg、1次/d,無因不良反應停止治療者。結論舒尼替尼2/1方案一線治療轉移性腎細胞癌患者的療效較好,患者耐受性好,3~4度不良反應髮生率較低,PFS有延長趨勢。
목적:관찰서니체니복약2주、정약1주방안(2/1방안)일선치료전이성신세포암환자적료효급안전성。방법경병리증실적11례전이성신투명세포암환자채용서니체니2/1방안치료,즉서니체니50 mg、1차/d,복약2주,정약1주,매6주위1개주기,지속사용지질병진전혹불량반응불능내수。주요관찰종점위무진전생존시간(PFS),차요종점위총생존시간(OS)、불량반응급객관완해솔。결과11례환자중,부분완해5례,질병은정3례,질병진전3례,객관완해솔위45.5%,질병공제솔위72.7%,중위PFS위17.0개월(95%CI위7.3~26.7개월),중위OS위26.0개월(95%CI위2.2~49.8개월)。주요불량반응위골수억제(백세포강저、혈소판강저)、복사、점막염화수족피부반응등,2례환자인불량반응서니체니감량지37.5 mg、1차/d,무인불량반응정지치료자。결론서니체니2/1방안일선치료전이성신세포암환자적료효교호,환자내수성호,3~4도불량반응발생솔교저,PFS유연장추세。
Objective To investigate the efficacy and safety of sunitinib as first-line therapy for metastatic renal cell carcinoma ( mRCC) on a 2 weeks on/1 week off intermittent dosing schedule.Methods A total of 11 mRCC patients were enrolled to receive sunitinib 50 mg/day in 2 weeks on/1 week off schedule per 6 weeks till disease progression or intolerable toxicity occurred.The primary end point was progression free survival ( PFS) , the secondary end points were overall survival ( OS) , incidence of adverse effects and objective response.Results The objective response rate in the 11 cases was 45.5%and disease control rate 72.7%( partial response n=5, stable disease n=3) .Till the last follow up on Dec 2013, the median PFS was 17.0 months (95%CI 7.3 to 26.7 months), and median OS 26.0 months (95%CI 2.2 to 49.8 months). The common adverse events included leucopenia, thrombocytopenia, diarrhea, mucositis and hand-foot skin reaction.Dose reduction to 37.5 mg was seen only in 2 patients without discontinuation. Conclusions Sunitinib on an intermittent dosing schedule 2 weeks on /1 week off as first-line therapy for mRCC patients shows a good efficacy and tolerance, with less grade 3-4 drug-related toxicities and a tendency of prolonged PFS in mRCC patients.